ADC
Current Location:HOME > Products > New compounds > ADC >
ADC
  Product Name:MMAE
  • CAS No.:474645-27-7
  • Formule:C39H67N5O72
  • Weight:717.97900
  • Purity: 98%
  •  
    MMAE Basic Properties and physical properties
    MMAE Basic Properties and physical properties
    Product Name MMAE
    CAS No 474645-27-7
    Formule C39H67N5O7
    Weight 717.97900
    Storage conditions 2-8°C
    Purity 98%
    Physical state powder
    Melting point: ND
    boiling point ND
    solubility ND
    Packing Bagged
    Supply 1000g
    LogP ND
    PSA ND
    Use Experimental use
    Place of Origin China
    Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.
    MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.
    Product Name MMAE
    CAS No 474645-27-7
    Formule C39H67N5O7
    Weight 717.97900
    Storage conditions 2-8°C
    Purity 98%
    Physical state powder
    Melting point: ND
    boiling point ND
    solubility ND
    Packing Bagged
    Supply 1000g
    LogP ND
    PSA ND
    Use Experimental use
    Place of Origin China
    Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.
    MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.





    Product Name:MMAE
    CAS No.:474645-27-7 Formule:C39H67N5O7 Weight:717.97900 Purity: 98%
    • Email:wzh@dmksw.xin
    • Email:gq@dmksw.xin
    • Telephone:8613260607296(SKYPE)
    • Telephone:8618942921723(SKYPE)






    Key words:MMAE(CAS No.:474645-27-7)
    Products introduction:Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells.
    • Products details
    • Products information
    • Buyer Transaction
    MMAE Basic Properties and physical properties
    Product Name MMAE
    CAS No 474645-27-7
    Formule C39H67N5O7
    Weight 717.97900
    Storage conditions 2-8°C
    Purity 98%
    Physical state powder
    Melting point: ND
    boiling point ND
    solubility ND
    Packing Bagged
    Supply 1000g
    LogP ND
    PSA ND
    Use Experimental use
    Place of Origin China
    Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.
    MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.





    Leave a message

    Your Name:
    E-mail:
    Phone:
    Company:
    Title:
    Content: